GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Integrated Biopharma Inc (OTCPK:INBP) » Definitions » PEG Ratio

Integrated Biopharma (Integrated Biopharma) PEG Ratio : N/A (As of May. 20, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Integrated Biopharma PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Integrated Biopharma's PE Ratio without NRI is 0.00. Integrated Biopharma's 5-Year EBITDA growth rate is -6.50%. Therefore, Integrated Biopharma's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Integrated Biopharma's PEG Ratio or its related term are showing as below:


During the past 13 years, Integrated Biopharma's highest PEG Ratio was 4.22. The lowest was 0.13. And the median was 0.37.


INBP's PEG Ratio is not ranked *
in the Consumer Packaged Goods industry.
Industry Median: 1.51
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Integrated Biopharma PEG Ratio Historical Data

The historical data trend for Integrated Biopharma's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integrated Biopharma PEG Ratio Chart

Integrated Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.37 0.54 0.27 -

Integrated Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Integrated Biopharma's PEG Ratio

For the Packaged Foods subindustry, Integrated Biopharma's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integrated Biopharma's PEG Ratio Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Integrated Biopharma's PEG Ratio falls into.



Integrated Biopharma PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Integrated Biopharma's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/-6.50
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


Integrated Biopharma  (OTCPK:INBP) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Integrated Biopharma PEG Ratio Related Terms

Thank you for viewing the detailed overview of Integrated Biopharma's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Integrated Biopharma (Integrated Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
225 Long Avenue, Building 15, Hillside, NJ, USA, 07205
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments; Contract Manufacturing and Other Nutraceutical Businesses. It serves the needs of the nutraceutical industry by directly doing business as Chem International Inc. and through its operating subsidiaries; Manhattan Drug Company, Inc., AgroLabs, Inc., IHT Health Products, Inc. and MDC Warehousing and Distribution, Inc. The company generates maximum revenue from the Contract Manufacturing segment. The business operates and generates the majority of revenue from the United States.
Executives
Damon Desantis director 2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
William H. Milmoe director, 10 percent owner 3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Joseph Laplaca director 72 EUGENE DRIVE, MONTVILLE NJ 07045
E Gerald Kay director, 10 percent owner, officer: Chairman and CEO C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Bradley J Hoecker director STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Jeffrey R Leach director, officer: President and CEO
Glenn Chang director C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Vidadi Yusibov director C/O IBIOPHARMA, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Cd Financial, Llc 10 percent owner 3299 N.W. 2ND AVENUE, BOCA RATON FL 33431
Kay Riva director, officer: Vice President C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Christina Kay director, officer: Vive President C/O 225 LONG AVENUE, HILLSIDE NJ 07205
Robert Canarick director C/O INTEGRATED BIOPHARMA, INC., 201 ROUTE 22, HILLSIDE NJ 07205
Robert Kay director C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Dina Masi officer: Chief Financial Officer 14 LEXINGTON WAY, LONG VALLEY NJ 07853
Carl Desantis director, 10 percent owner C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431